UK Biopharmaceuticals Contract Manufacturing Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Description
Market Overview
The UK Biopharmaceuticals Contract Manufacturing Market is anticipated to grow significantly, increasing from USD 744.76 million in 2023 to approximately USD 2,724.71 million by 2032, registering a compound annual growth rate (CAGR) of 15.50% over the forecast period (2024–2032).
This robust expansion is being driven by the growing demand for cost-effective, scalable, and specialized drug manufacturing solutions. As pharmaceutical companies face rising R&D costs and increasing complexity in biologics production, many are turning to contract manufacturing organizations (CMOs) to streamline operations and accelerate time-to-market. The evolution of biologics, biosimilars, and personalized medicine has further intensified the need for advanced manufacturing capabilities—an area where UK-based CMOs offer strong expertise and infrastructure.
In addition, the UK's well-established regulatory environment, skilled workforce, and access to cutting-edge technologies provide an attractive setting for outsourcing. As sustainability becomes an integral part of the pharmaceutical supply chain, contract manufacturers are also adapting by integrating eco-friendly, cost-efficient processes, thereby opening up new avenues for innovation and long-term strategic partnerships.
Market Drivers
1. Cost Efficiency and Specialized Expertise
Outsourcing biopharmaceutical manufacturing enables companies to significantly reduce capital expenditure, improve cost-efficiency, and focus resources on core activities such as drug discovery and commercialization. Contract manufacturers bring to the table advanced infrastructure, experienced personnel, and in-depth regulatory knowledge, reducing the operational burden for biopharma firms.
The performance of the UK biopharmaceutical sector reflects this efficiency; for example, the sector reported a £108.1 billion turnover in 2021/22, underlining the economic viability and growing reliance on contract manufacturing. This shift allows biopharma companies to manage risks, scale production quickly, and ensure compliance with ever-evolving global standards.
Market Challenges
1. Regulatory Complexity and Compliance Costs
Despite its growth potential, the UK biopharmaceutical contract manufacturing sector faces notable regulatory hurdles. Adherence to stringent global and local standards—such as Good Manufacturing Practices (GMP)—requires continuous investment in training, audits, and infrastructure upgrades.
Post-Brexit regulatory changes have added another layer of complexity, requiring manufacturers to navigate new protocols and compliance structures for both UK and EU markets. For example, the sector invested over £9 billion in R&D during 2021/22 to support regulatory alignment and quality assurance. These investments, while necessary, increase operational costs and can result in production delays if not managed effectively.
Market Segmentation
By Source
Mammalian
Non-mammalian
By Service Type
Process Development
Upstream Processing
Downstream Processing
Fill & Finish Operations
Analytical & Quality Control (QC) Studies
Packaging & Labelling
Other Services
By Drug Type
Biologics
Monoclonal Antibodies (mAbs)
Recombinant Proteins
Vaccines
Antisense, RNAi, & Molecular Therapy
Others
Biosimilars
By Product Type
Drug Substance
Finished Drug Product
By Scale of Operation
Clinical
Commercial
By Therapeutic Area
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Infectious Diseases
Others
By Geography
London
Manchester
Birmingham
Scotland
Key Market Players
Fareva Holdings SA
Recipharm AB
Boehringer Ingelheim Group
Aenova Group
Famar SA
Lonza Group
Cenexi – Laboratoires Thissen SA
Almac Group
The UK Biopharmaceuticals Contract Manufacturing Market is anticipated to grow significantly, increasing from USD 744.76 million in 2023 to approximately USD 2,724.71 million by 2032, registering a compound annual growth rate (CAGR) of 15.50% over the forecast period (2024–2032).
This robust expansion is being driven by the growing demand for cost-effective, scalable, and specialized drug manufacturing solutions. As pharmaceutical companies face rising R&D costs and increasing complexity in biologics production, many are turning to contract manufacturing organizations (CMOs) to streamline operations and accelerate time-to-market. The evolution of biologics, biosimilars, and personalized medicine has further intensified the need for advanced manufacturing capabilities—an area where UK-based CMOs offer strong expertise and infrastructure.
In addition, the UK's well-established regulatory environment, skilled workforce, and access to cutting-edge technologies provide an attractive setting for outsourcing. As sustainability becomes an integral part of the pharmaceutical supply chain, contract manufacturers are also adapting by integrating eco-friendly, cost-efficient processes, thereby opening up new avenues for innovation and long-term strategic partnerships.
Market Drivers
1. Cost Efficiency and Specialized Expertise
Outsourcing biopharmaceutical manufacturing enables companies to significantly reduce capital expenditure, improve cost-efficiency, and focus resources on core activities such as drug discovery and commercialization. Contract manufacturers bring to the table advanced infrastructure, experienced personnel, and in-depth regulatory knowledge, reducing the operational burden for biopharma firms.
The performance of the UK biopharmaceutical sector reflects this efficiency; for example, the sector reported a £108.1 billion turnover in 2021/22, underlining the economic viability and growing reliance on contract manufacturing. This shift allows biopharma companies to manage risks, scale production quickly, and ensure compliance with ever-evolving global standards.
Market Challenges
1. Regulatory Complexity and Compliance Costs
Despite its growth potential, the UK biopharmaceutical contract manufacturing sector faces notable regulatory hurdles. Adherence to stringent global and local standards—such as Good Manufacturing Practices (GMP)—requires continuous investment in training, audits, and infrastructure upgrades.
Post-Brexit regulatory changes have added another layer of complexity, requiring manufacturers to navigate new protocols and compliance structures for both UK and EU markets. For example, the sector invested over £9 billion in R&D during 2021/22 to support regulatory alignment and quality assurance. These investments, while necessary, increase operational costs and can result in production delays if not managed effectively.
Market Segmentation
By Source
Mammalian
Non-mammalian
By Service Type
Process Development
Upstream Processing
Downstream Processing
Fill & Finish Operations
Analytical & Quality Control (QC) Studies
Packaging & Labelling
Other Services
By Drug Type
Biologics
Monoclonal Antibodies (mAbs)
Recombinant Proteins
Vaccines
Antisense, RNAi, & Molecular Therapy
Others
Biosimilars
By Product Type
Drug Substance
Finished Drug Product
By Scale of Operation
Clinical
Commercial
By Therapeutic Area
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Infectious Diseases
Others
By Geography
London
Manchester
Birmingham
Scotland
Key Market Players
Fareva Holdings SA
Recipharm AB
Boehringer Ingelheim Group
Aenova Group
Famar SA
Lonza Group
Cenexi – Laboratoires Thissen SA
Almac Group
Table of Contents
199 Pages
- Executive Summary
- 1.1. Market Highlights
- 1.2. Key Market Insights
- 1.3. Strategic Recommendations
- 1.4. UK Market Snapshot
- Introduction
- 2.1. Report Objectives
- 2.2. Scope of the Study
- 2.3. Research Methodology
- 2.4. Assumptions and Limitations
- Market Overview
- 3.1. Market Definition
- 3.2. Evolution of Biopharmaceutical Contract Manufacturing
- 3.3. Market Drivers
- 3.4. Market Restraints
- 3.5. Market Opportunities
- 3.6. Challenges in the Market
- 3.7. Value Chain Analysis
- 3.8. Regulatory Framework in the UK
- UK Biopharmaceuticals Contract Manufacturing Market Outlook
- 4.1. Market Size and Forecast (2024–2030)
- 4.2. Market Share Analysis
- 4.3. Industry Trends and Emerging Technologies
- 4.4. Competitive Benchmarking
- Market Segmentation
- 5.1. Based on Source
- 5.1.1. Mammalian
- 5.1.2. Non-mammalian (Microbial, Insect, Plant, etc.)
- 5.2. Based on Service
- 5.2.1. Process Development
- 5.2.2. Fill & Finish Operations
- 5.2.3. Analytical and QC Studies
- 5.2.4. Packaging
- 5.2.5. Others
- 5.3. Based on Drug Type
- 5.3.1. Monoclonal Antibodies
- 5.3.2. Vaccines
- 5.3.3. Recombinant Proteins
- 5.3.4. Cell & Gene Therapies
- 5.3.5. Others
- 5.4. Based on Type
- 5.4.1. Innovator Drugs
- 5.4.2. Biosimilars
- 5.5. Based on Scale of Operation
- 5.5.1. Preclinical
- 5.5.2. Clinical
- 5.5.3. Commercial
- 5.6. Based on Therapeutic Area
- 5.6.1. Oncology
- 5.6.2. Infectious Diseases
- 5.6.3. Autoimmune Diseases
- 5.6.4. Cardiovascular Disorders
- 5.6.5. Neurological Disorders
- 5.6.6. Others
- 5.7. Based on Geography
- 5.7.1. England
- 5.7.2. Scotland
- 5.7.3. Wales
- 5.7.4. Northern Ireland
- Competitive Landscape
- 6.1. Market Share Analysis (by Revenue, 2024)
- 6.2. Key Strategies Adopted by Leading Players
- 6.2.1. Collaborations & Partnerships
- 6.2.2. Mergers & Acquisitions
- 6.2.3. Facility Expansions
- 6.2.4. Technological Advancements
- Key Player Analysis
- 7.1. Fareva Holdings SA
- 7.2. Recipharm AB
- 7.3. Boehringer Ingelheim Group
- 7.4. Aenova Group
- 7.5. Famar SA
- 7.6. Lonza Group
- 7.7. Cenexi – Laboratoires Thissen SA
- 7.8. Almac Group
- Market Outlook and Future Opportunities
- 8.1. Emerging Therapeutic Areas
- 8.2. Advances in Biomanufacturing Technologies
- 8.3. Strategic Investment Opportunities
- 8.4. Impact of Brexit and Evolving Regulations
- Appendix
- 9.1. Glossary
- 9.2. Abbreviations
- 9.3. References
- 9.4. Research Methodology Overview
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
